Copyright 2009 Medical News Today Latest Lymphoma / Leukemia News From Medical News Today. http://www.medicalnewstoday.com/sections/lymphoma-leukemia/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 04 Jul 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/156357.php http://www.medicalnewstoday.com/articles/156357.php New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer. The study, published by Cell Press in the July 2nd issue of the journal Cell Stem Cell, describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of leukemia. Lymphoma / Leukemia Thu, 02 Jul 2009 05:00:00 PDT http://www.medicalnewstoday.com/articles/156179.php http://www.medicalnewstoday.com/articles/156179.php Janet Davison Rowley, MD, a founder in the field of cancer cytogenetics and a renowned leader in molecular oncology, will receive the 2009 Genetics Prize of The Peter and Patricia Gruber Foundation. She is being honored with the prestigious international award for discoveries of recurrent chromosomal abnormalities in leukemias and lymphomas - discoveries that have revolutionized how cancer is understood and treated. Lymphoma / Leukemia Wed, 01 Jul 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/155949.php http://www.medicalnewstoday.com/articles/155949.php The Damon Runyon Cancer Research Foundation named 4 new Damon Runyon Clinical Investigators at its April 2009 Clinical Investigator Award Committee review. The recipients of this prestigious, three-year award are outstanding early career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation's leading scientists and clinicians. Each will receive $450,000 to support the development of his cancer research program. Cancer / Oncology Wed, 01 Jul 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/155953.php http://www.medicalnewstoday.com/articles/155953.php CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical trial to evaluate the efficacy and safety of orally administered tamibarotene as a third-line treatment for acute promyelocytic leukemia (APL). Lymphoma / Leukemia Tue, 30 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/155782.php http://www.medicalnewstoday.com/articles/155782.php New data show that at 24 months, patients in the chronic phase of Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) who are intolerant or resistant to current first-line therapy (Glivec) experienced a rapid response and significant reduction in leukaemia burden when treated with 400mg Tasigna twice-daily1. Lymphoma / Leukemia Tue, 30 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/155794.php http://www.medicalnewstoday.com/articles/155794.php Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID®, Biovest's personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Lymphoma / Leukemia Tue, 30 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/155738.php http://www.medicalnewstoday.com/articles/155738.php Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Lymphoma / Leukemia Sat, 27 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/155583.php http://www.medicalnewstoday.com/articles/155583.php Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells. Lymphoma / Leukemia Thu, 25 Jun 2009 06:00:00 PDT http://www.medicalnewstoday.com/articles/155337.php http://www.medicalnewstoday.com/articles/155337.php Effective drugs for treating a chemotherapy-resistant form of lymphoma might already be on the market according to a study that has pieced together a chemical pathway involved in the disease. Cancer / Oncology Thu, 25 Jun 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/155285.php http://www.medicalnewstoday.com/articles/155285.php Almost 60 mantle cell lymphoma (MCL) specialists from around the world gathered in Atlanta, GA for the Lymphoma Research Foundation's (LRF) Sixth Annual Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop. Attendees heard presentations addressing several key issues including the biology of MCL, prognostic indicators, new molecular targets, chemoimmunotherapy, transplantation and novel therapeutic approaches. Lymphoma / Leukemia Thu, 25 Jun 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/155255.php http://www.medicalnewstoday.com/articles/155255.php Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS). Lymphoma / Leukemia Wed, 24 Jun 2009 04:00:00 PDT http://www.medicalnewstoday.com/articles/155121.php http://www.medicalnewstoday.com/articles/155121.php Australian regenerative medicine company Mesoblast Limited has announced successful results from the first five patients who underwent bone marrow transplantation with haematopoietic stem and progenitor cells expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs). The Phase I/II trial in up to 30 patients is being conducted by Mesoblast's US-based associated company Angioblast Systems Inc. at the University of Texas M. D. Lymphoma / Leukemia Wed, 24 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/155017.php http://www.medicalnewstoday.com/articles/155017.php BloodCenter of Wisconsin's Diagnostic Laboratories announced that it is the first laboratory in the United States to develop and offer a genetic test, known as "CEBPA Mutation Analysis," for inherited acute myeloid leukemia (AML). AML is the second most common form of leukemia. The link between inherited variants in the CEBPA gene and the familial form of acute myeloid leukemia (AML) was first described in the New England Journal of Medicine in 2004. Lymphoma / Leukemia Tue, 23 Jun 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/154908.php http://www.medicalnewstoday.com/articles/154908.php A groundbreaking study conducted by Children's Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman's placenta, or more specifically the discarded placentas of healthy newborns. The study also finds there are far more stem cells in placentas than in umbilical cord blood, and they can be safely extracted for transplantation. Stem Cell Research Sun, 21 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/154734.php http://www.medicalnewstoday.com/articles/154734.php Seattle Genetics, Inc. (NASDAQ:SGEN), announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs. Lymphoma / Leukemia Sat, 20 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/154703.php http://www.medicalnewstoday.com/articles/154703.php Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. Lymphoma / Leukemia Fri, 19 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/154573.php http://www.medicalnewstoday.com/articles/154573.php George Dahlman, senior vice president of public policy for The Leukemia & Lymphoma Society (LLS), testified today before the U.S. Senate Subcommittee on Defense Appropriations, calling for funding for a dedicated, stand-alone blood cancer research program at the Department of Defense (DoD). Lymphoma / Leukemia Fri, 19 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/154533.php http://www.medicalnewstoday.com/articles/154533.php Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke, according to a new study published June 17 online in the Journal of the National Cancer Institute. The study was undertaken because information on clinically verified stroke and transient ischemic attack (TIA), or a "mini stroke," following Hodgkin lymphoma is limited. In order to quantify the long-term risks, Flora E. van Leeuwen, Ph.D. Lymphoma / Leukemia Thu, 18 Jun 2009 06:00:00 PDT http://www.medicalnewstoday.com/articles/154407.php http://www.medicalnewstoday.com/articles/154407.php A review of the NICE decision on the approval of lenalidomide is published in a special report Online First and in the July edition of The Lancet Oncology. About 2,000 multiple myeloma sufferers in the UK could benefit from the drug and improve their life expectancy pending a decision by The UK National Institute for Health and Clinical Excellence (NICE). Lymphoma / Leukemia Thu, 18 Jun 2009 03:00:00 PDT http://www.medicalnewstoday.com/articles/154381.php http://www.medicalnewstoday.com/articles/154381.php Despite great strides in treating childhood leukemia, a form of the disease called T-cell acute lymphoblastic leukemia (T-ALL) poses special challenges because of the high risk of leukemic cells invading the brain and spinal cord of children who relapse. Now, a new study in the June 18, 2009, issue of the journal Nature by scientists at NYU School of Medicine reveals the molecular agents behind this devastating infiltration of the central nervous system. Lymphoma / Leukemia Thu, 18 Jun 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/154374.php http://www.medicalnewstoday.com/articles/154374.php Clavis Pharma ASA (OSE: CLAVIS) announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned. Lymphoma / Leukemia Tue, 16 Jun 2009 02:00:00 PDT http://www.medicalnewstoday.com/articles/153980.php http://www.medicalnewstoday.com/articles/153980.php Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break - an occurrence that marks the first step in the development of human lymphoma. The study provides researchers with the clearest insight yet into why these breakages - called chromosomal translocations - occur at a specific points in the chromosome, says principal investigator Michael R. Lieber, M.D., Ph.D. Lymphoma / Leukemia Tue, 16 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/153978.php http://www.medicalnewstoday.com/articles/153978.php A protein known to play a role in growth of some types of leukemia appears to have a mixed function in breast cancer development, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC). Lymphoma / Leukemia Tue, 16 Jun 2009 01:00:00 PDT http://www.medicalnewstoday.com/articles/153984.php http://www.medicalnewstoday.com/articles/153984.php The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study. Lymphoma / Leukemia Sat, 13 Jun 2009 00:00:00 PDT http://www.medicalnewstoday.com/articles/153651.php http://www.medicalnewstoday.com/articles/153651.php A new study suggests that delivering small RNAs, known as microRNAs, to cancer cells could help to stop the disease in its tracks. microRNAs control gene expression and are commonly lost in cancerous tumors. Researchers have shown that replacement of a single microRNA in mice with an extremely aggressive form of liver cancer can be enough to halt their disease, according to a report in the June 12 issue of the journal Cell, a Cell Press publication. Cancer / Oncology